Victoza Sales Lift Novo Nordisk 2010 Forecasts
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong Victoza roll-out and setback to Bydureon help boost outlook for Novo Nordisk.
You may also be interested in...
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
If FDA approves the new protocol, a QT prolongation study required to refile Bydureon could commence this quarter.
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
If FDA approves the new protocol, a QT prolongation study required to refile Bydureon could commence this quarter.
2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound
After several years of either niche or me-too drug launches, 2010 brought an encouraging wave of new molecular entities and novel biologics to market, including several first-in-class drugs addressing large therapeutic areas.